YD Bio Limited Quality Score
YDES
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
Above 10% CAGR, strong compounder
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Contracted >2pp, margin pressure
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
YD Bio (YDES) quality: score, margins and returns
YD Bio (YDES) scores 25/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 5 metrics each scored 0 to 100, on -882.7% operating margins and -125.8% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is YD Bio (YDES) a high-quality business?+
YD Bio scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -882.7% operating margin and a -125.8% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does YD Bio's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from YDES's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where YD Bio scores well and where it falls behind.
What is YD Bio's return on invested capital (ROIC)?+
YD Bio earns about -125.8% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to YDES's margins and growth on this scorecard to judge durability.
How profitable is YD Bio?+
YD Bio runs an operating margin of about -882.7% and a net margin of about -1,392.6%. Revenue has grown at roughly 30.6% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.
Peers
Biotechnology · Pick stocks to compare with YDES
Held by ETFs
YDES is in 1 US ETF. The largest of them, with YDES's weight in each:
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing YDES
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.